rct
    2020
    High Quality

    Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis

    Paganoni S, Macklin EA, Hendrix S

    Published in New England Journal of Medicine

    Methodology

    Randomized double-blind placebo-controlled phase II CENTAUR trial of sodium phenylbutyrate-taurursodiol in ALS over 24 weeks

    Key Findings

    The active combination slowed ALSFRS-R decline compared with placebo over 24 weeks

    Conclusions

    The phenylbutyrate-taurursodiol combination slowed functional decline in ALS in a phase II trial

    Limitations

    Combination product; phase II; the later larger phase III did not confirm benefit

    Supplements Studied

    TUDCA
    Compound

    Sodium phenylbutyrate-taurursodiol slowed ALSFRS-R decline compared with placebo over 24 weeks

    Outcomes Measured

    Neuroprotection

    Sodium phenylbutyrate-taurursodiol slowed ALSFRS-R decline over 24 weeks

    Study Details

    Year:2020
    Sample Size:137
    Duration:24 weeks
    Quality Score:7/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.